Abstract
Kruppel-like factor (KLF) family members share a three C2H2 zinc finger DNA binding domain, and are involved in cell proliferation and differentiation control in normal as in pathological situations. Studies over the past several years support a significant role for this family of transcription factors in carcinogenesis. KLFs can both activate and repress genes that participate in cell-cycle regulation. Among them, many up-regulated genes are inhibitors of proliferation, whereas genes that promote cell proliferation are repressed. However, several studies do present KLFs as positive regulator of cell proliferation. KLFs can be deregulated in multiple cancers either by loss of heterozygosity (LOH), somatic mutation or transcriptional silencing by promoter hypermethylation. Accordingly, KLF expression was shown to mediate growth inhibition when ectopically expressed in multiple cancer-derived cell lines through the inhibition of a number of key oncogenic signaling pathways, and to revert the tumorogenic phenotype in vivo. Taken together, these observations suggest that KLFs act as tumor suppressor. However, in some occasion, KLFs could act as tumor promoters, depending on “cellular context”. Thus, this review will discuss the roles and the functions of KLF family members in carcinogenesis, with a special focus on cancers from epithelial origin.
Current Genomics
Title: Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Volume: 10 Issue: 5
Author(s): Christophe Bureau, Naima Hanoun, Jerome Torrisani, Jean-Pierre Vinel, Louis Buscail and Pierre Cordelier
Affiliation:
Abstract: Kruppel-like factor (KLF) family members share a three C2H2 zinc finger DNA binding domain, and are involved in cell proliferation and differentiation control in normal as in pathological situations. Studies over the past several years support a significant role for this family of transcription factors in carcinogenesis. KLFs can both activate and repress genes that participate in cell-cycle regulation. Among them, many up-regulated genes are inhibitors of proliferation, whereas genes that promote cell proliferation are repressed. However, several studies do present KLFs as positive regulator of cell proliferation. KLFs can be deregulated in multiple cancers either by loss of heterozygosity (LOH), somatic mutation or transcriptional silencing by promoter hypermethylation. Accordingly, KLF expression was shown to mediate growth inhibition when ectopically expressed in multiple cancer-derived cell lines through the inhibition of a number of key oncogenic signaling pathways, and to revert the tumorogenic phenotype in vivo. Taken together, these observations suggest that KLFs act as tumor suppressor. However, in some occasion, KLFs could act as tumor promoters, depending on “cellular context”. Thus, this review will discuss the roles and the functions of KLF family members in carcinogenesis, with a special focus on cancers from epithelial origin.
Export Options
About this article
Cite this article as:
Bureau Christophe, Hanoun Naima, Torrisani Jerome, Vinel Jean-Pierre, Buscail Louis and Cordelier Pierre, Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis, Current Genomics 2009; 10 (5) . https://dx.doi.org/10.2174/138920209788921010
DOI https://dx.doi.org/10.2174/138920209788921010 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Intravesical Drug Delivery into the Bladder to Treat Cancers
Current Drug Delivery Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design Organic Synthesis and Antisense Effects of Oligonucleotide-Peptide Conjugates
Current Organic Chemistry Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Inhibitors and Prodrugs Targeting CYP1: A Novel Approach in Cancer Prevention and Therapy
Current Medicinal Chemistry A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets Current Uses of Robotic Surgery for the Treatment of Benign Adnexal Conditions
Current Women`s Health Reviews Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry